Imugene Ltd (ASX:IMU, OTC:IUGNF) has signed up a chief financial officer (CFO) to a newly created in-house role which will see Mike Tonroe lead the company’s finance function.
Tonroe has extensive experience as a CFO and company secretary in the biopharmaceutical industry and brings international finance leadership experience from his time in the US, Canada, the UK and Hong Kong.
NASDAQ, M&A and cap-raising experience
His most recent role was as CFO and company secretary at ASX and NASDAQ-listed Genetic Technologies (ASX:GTG) Limited and Opthea Limited, where he managed the US IPO and NASDAQ listing of Opthea.
He also led finance at these businesses, conducting an M&A, restructure and capital raising.
Before this he held a similar role at private business Australian Synchotron Company Ltd.
Tonroe has a breadth of experience informed by his exposure to the technology, energy and travel sectors from earlier roles, which also include time with major accounting firms KPMG and Deloitte.
He graduated in Business Studies with Honours from Buckingham University in the UK, later becoming a member then fellow of the Institute of Chartered Accountants in England and Wales and being Australian Institute of Company Directors accredited.
Expertise, business-stage and culture fit
Imugene managing director and CEO Leslie Chong said: “We've undertaken an extensive search recently to fill this important role within the business, with a view to finding someone that fits both in terms of expertise and the stage of the business, but also suits the culture at Imugene which we take great pride in.
“Mike is an outstanding appointment on these fronts and we are eager to see the positive impact his contribution will make to Imugene and the team.”
Tonroe will start subject to finalisation of his current transition arrangements, around early September.